Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding a dense lab notebook. Coya Therapeutics’ 10-K alone weaves Treg science, trial data, and cash-runway math into over a hundred pages. If you are searching “Coya Therapeutics SEC filings explained simply” or wondering which executive bought shares before the next ALS data release, this page was built for you.
Stock Titan’s AI pinpoints the science and the numbers that matter. Our platform surfaces:
- Coya Therapeutics annual report 10-K simplified—see R&D expense trends and pipeline milestones without skimming footnotes.
- Coya Therapeutics quarterly earnings report 10-Q filing—quickly compare cash burn and trial costs quarter over quarter.
- Coya Therapeutics Form 4 insider transactions real-time—track executive stock moves as soon as they hit EDGAR.
- Coya Therapeutics 8-K material events explained—get plain-English summaries when new clinical data or FDA feedback lands.
- Coya Therapeutics proxy statement executive compensation—understand how milestone bonuses align with Treg therapy progress.
Every document is paired with an AI-powered summary, highlighting cash runway estimates, Treg therapy development stages, and key risk factors—ideal for investors asking “How do I analyze Coya Therapeutics’ earnings report filing?” or “Where can I find Coya Therapeutics insider trading Form 4 transactions?”. Real-time alerts, historical archives, and side-by-side form comparisons mean you spend minutes, not hours, extracting insight.
Whether you monitor Coya Therapeutics executive stock transactions Form 4 before Phase 2 data or need a concise view of collaborative revenue in the latest 10-Q, our AI turns complex immunology jargon into actionable clarity.
Coya Therapeutics is offering securities on a shelf registration for up to $75,000,000 to sell common stock, preferred stock, warrants, debt securities, subscription rights and units from time to time. The company is clinical-stage, focused on therapies that enhance regulatory T cells (Tregs), with lead asset COYA 302 (a combination of low-dose IL-2 and CTLA4-Ig) and an autologous Treg program that completed Phase 1 and Phase 2a studies in ALS.
Pipeline expansion includes COYA 303, a LD IL-2 plus GLP-1RA combination. A published preclinical study reported COYA 303 increased Treg suppressive function by 42% (p < 0.001) versus single agents (15% and 20%), and reduced BAX transcripts (p < 0.01), suggesting enhanced Treg survival. The company resubmitted an IND for the planned COYA 302 Phase 2 ALS study and the FDA has delayed its initial review, indicating a decision expected no later than August 29, 2025.
Financially, Coya reported net losses of $13.4 million for the six months ended June 30, 2025, an accumulated deficit of $54.1 million, and had 16,725,081 common shares outstanding; the last reported Nasdaq sale price was $6.15 per share. The company qualifies as an emerging growth company and elected the extended transition for new accounting standards.
Coya Therapeutics held $29.8 million in cash and cash equivalents as of June 30, 2025 and reported an accumulated deficit of $54.1 million. The company recorded a net loss of $6.09 million for the three months and $13.40 million for the six months ended June 30, 2025. Collaboration revenue declined to $163,616 for the quarter and $421,500 for the six months, versus substantially higher amounts in the prior-year periods driven by upfront license recognition in 2024.
The balance sheet shows $1.372 million in deferred collaboration revenue. Under the DRL Development Agreement the company received a prior upfront payment of $7.5 million and $3.9 million in a June 2024 amendment; remaining R&D services revenue is being recognized over time. The company resubmitted an IND for COYA 302 on June 30, 2025 and disclosed the FDA told the company it cannot meet the initial review goal date but expects to provide a decision no later than August 29, 2025. Management states existing cash should fund operations for at least one year after issuance of these financial statements, and that substantial additional financing will be required thereafter.
Coya Therapeutics (NASDAQ:COYA) filed a Form 8-K reporting the results of its June 26, 2025 Annual Meeting of Stockholders.
- Directors re-elected: Howard Berman, Ph.D. (5,821,649 for), Arun Swaminathan, Ph.D. (6,324,520 for), and Ann Lee, Ph.D. (5,779,312 for); broker non-votes totaled 4,096,866 shares.
- Auditor ratified: Weaver & Tidwell, L.L.P. was approved as independent registered public accounting firm for FY 2025 with 10,355,085 votes for (98.9%), 68,851 against, and 340 abstentions.
No additional proposals were presented and the filing discloses no material changes to operations, strategy, or governance.
FAQ
What is the current stock price of Coya Therapeutics (COYA)?
What is the market cap of Coya Therapeutics (COYA)?
